Navigation Links
ContraVir to Present at Two Upcoming Investor Conferences
Date:9/3/2014

EDISON, N.J., Sept. 3, 2014 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), an emerging biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it will present at two upcoming investor conferences. ContraVir is scheduled to present at the Rodman & Renshaw 16th Annual Global Investment Conference, to be held September 8-10, 2014, in New York City, and the Aegis Capital 2014 Healthcare and Technology Conference, to be held September 10-13, 2014 in Las Vegas.

James Sapirstein, Chief Executive Officer, will provide an overview of the Company's business during his live presentations and will be available to participate in one-on-one meetings with investors who are registered to attend the conferences.  Event:Rodman & Renshaw 16th Annual Global Investment ConferenceDate:  

Tuesday, September 9, 2014 Time:  

4:10 pm (Eastern Time)Location:New York Palace Hotel, New York, NY  Event: Aegis Capital 2014 Healthcare and Technology ConferenceDate:  

Thursday, September 11, 2014 Time:  

1:30 pm (Pacific Time) Location: The Encore at Wynn, Las Vegas, NV  

About ContraVir PharmaceuticalsContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies. ContraVir's lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus (VZV). Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, famcyclovir, and valacyclovir, the FDA approved drug for treating shingles. Moreover, FV-100 has been shown to have a more rapid onset of antiviral activity in preclinical models, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels and with a better dosing regimen. Phase I trials of FV-100 in volunteers were successfully completed, as well as a Phase IIa clinical trial in shingles patients. ContraVir plans to conduct a Phase IIb trial in patients with shingles to further explore FV-100's potential to treat the long-lasting nerve pain typically associated with shingles. ContraVir was formed in May 2013 by Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) and spun off as an independent public company in January 2014. For more information, please visit www.contravir.com.

Forward Looking StatementsCertain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on ContraVir's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. ContraVir does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in ContraVir's Form 10-K for the year ended December 31, 2013 and other periodic reports filed with the Securities and Exchange Commission.

For further information, please contact:Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com; (212) 375-2664

Claire Sodja (media)
csojda@tiberend.com; (212) 375-2686


'/>"/>
SOURCE ContraVir Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
5. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
8. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
9. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
10. Anlit to Present New Dietary Supplements for Children at Vitafoods Europe 2012
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... MILWAUKEE , March 22, 2017 Serve You ... Custom Prescription Management, Inc. (Serve You), based in ... Order Pharmacy (NEMOP) business, based in Middlebury, Vermont ... positioning ourselves for geographic expansion, so it was perfect timing ... , President and CEO of Serve You. "Like us, NEMOP ...
(Date:3/22/2017)... N.J. , March 22, 2017  CANTEL MEDICAL CORP. ... B. Hansen , President and CEO, will be presenting at ... at the Westin Grand Central Hotel in New ... April 5, 2017 at 3:00 p.m. ET. In addition, management ... A live audio webcast will be available ...
(Date:3/22/2017)... -- Ablation is the minimally invasive therapeutic tissue excision ... from cancerous or diseased tissue removal, to the ... fibrillation and others. The growing adoption of minimally ... and improvise existing ablation technologies for better patient ... is expected to grow at high single digit ...
Breaking Medicine Technology:
(Date:3/23/2017)... , ... March 23, 2017 , ... “Beyond and Back”: ... and Back” is the creation of published author Bonetta Rose, a wife, mother and ... lives. , Published by Christian Faith Publishing, Bonetta Rose‘s new book presents actual events ...
(Date:3/23/2017)... ... March 23, 2017 , ... “My Journey Through Heaven”: ... with an infinitely more profound faith of God’s promise of Heaven for His people. ... who spends each day with his wife, three children and six grandchildren living and ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful ... “A Respectful Response To Atheist Manifesto” is the creation of published author Richard ... Nancy, for sixty years. He holds graduate degrees from Kent State University and ...
(Date:3/23/2017)... ... 23, 2017 , ... “More Corruption”: a simple and strong explanation of the God’s love. ... rulers of Heaven was asked by God to write a book about Him. , She ... because I kept my commitment to the Lord God. They have not walked in my ...
(Date:3/22/2017)... ... 2017 , ... Death anxiety is unconscious and needs understanding and non-judgmental support ... to write the book titled “ As Good as Goodbyes Get ” (published by ... what she was experiencing at the bedside of patients who were dying. The book ...
Breaking Medicine News(10 mins):